This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
17 Mar 2011

GSK Announces Positive Results of PD Clinical Study

GlaxoSmithKline has reported positive, top-line results of the ADVANCE-Parkinson's Disease Phase III clinical study.

GlaxoSmithKline announced positive, top-line results of the ADVANCE-Parkinson's Disease (PD) Phase III clinical study, conducted by Impax Pharmaceuticals, of IPX066 versus immediate-release (IR) carbidopa-levodopa (CD-LD) in advanced PD patients experiencing motor fluctuations.

 

IPX066 is an investigational extended release (ER) CD-LD product which is being developed by Impax in collaboration with GSK.

 

The study enrolled 471 subjects on a stable regimen of IR CD-LD who were first entered into a dose-adjustment phase of their IR CD-LD, then switched to open label IPX066 after which they were then randomised to double-blind IPX066 or IR CD-LD. Subjects switched to IPX066 experienced a total reduction in off-time from baseline of more than 2 hours du

Related News